ASH 2021 | Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
Sarah Tasian
• 13 Dec 2021
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses strategies to treat pediatric FLT3-mutant acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Pre-clinical studies investigating gilteritinib, a FLT3 inhibitor, have demonstrated that combining gilteritinib and chimeric antigen receptor (CAR) T-cell therapy was effective in the aforementioned patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
